Determining host factors contributing to the reactivation of JC virus in kidney transplant recipients.
Graft rejection
JC virus
Reactivation
Renal transplantation
Risk factors
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
08 08 2022
08 08 2022
Historique:
received:
27
11
2021
accepted:
18
05
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
11
8
2022
Statut:
epublish
Résumé
The John Cunningham virus (JCV) is the established etiological agent of the polyomavirus-associated nephropathy among renal transplant recipients. In the present study, we aimed to determine the probable predictive factors leading to JCV replication in renal transplant patients. Urine and plasma samples were collected from a total of 120 consecutive renal-transplanted patients without preliminary screening from Jan 2018 to Mar 2019. After DNA extraction, the simultaneous detection and quantification of JCV and BK polyomavirus (BKV) were conducted using a Real-time quantitative PCR method. Moreover, statistical analyses were performed using the statistical software packages, SPSS version 21. The prevalence of JCV viruria and viremia among renal transplant recipients were 26 (21.67%) and 20 (16.67%), respectively. A significant association was observed between the JCV and two risk factors, diabetes mellitus (P = 0.002) and renal stones (P = 0.015). The prevalence of JCV viremia among recipients who were grafted near time to sampling was significantly higher (P = 0.02). There was a statistically significant coexistence between BK and JC viruses among our patients (P = 0.029). The frequency of JCV viruria in males was reported almost three times more than in females (P = 0.005). The JCV shedding in urine was significantly associated with the tropical steroids like prednisolone acetate, which have been the standard regimen (P = 0.039). Multivariable analysis revealed duration of post-transplantation (OR, 0.89; P = 0.038), diabetes mellitus (OR, 1.85; P = 0.034), and renal stone (OR 1.10; P = 0.04) as independent risk factors associated with JCV viremia post-renal transplantation. It seems that the discovery of potential risk factors, including immunological and non-immunological elements, may offer a possible preventive or therapeutic approach in the JCV disease episodes. The results of this study may also help clarify the probable clinical risk factors involving in progressive multifocal leukoencephalopathy development.
Sections du résumé
BACKGROUND AND AIMS
The John Cunningham virus (JCV) is the established etiological agent of the polyomavirus-associated nephropathy among renal transplant recipients. In the present study, we aimed to determine the probable predictive factors leading to JCV replication in renal transplant patients.
MATERIAL AND METHODS
Urine and plasma samples were collected from a total of 120 consecutive renal-transplanted patients without preliminary screening from Jan 2018 to Mar 2019. After DNA extraction, the simultaneous detection and quantification of JCV and BK polyomavirus (BKV) were conducted using a Real-time quantitative PCR method. Moreover, statistical analyses were performed using the statistical software packages, SPSS version 21.
RESULTS
The prevalence of JCV viruria and viremia among renal transplant recipients were 26 (21.67%) and 20 (16.67%), respectively. A significant association was observed between the JCV and two risk factors, diabetes mellitus (P = 0.002) and renal stones (P = 0.015). The prevalence of JCV viremia among recipients who were grafted near time to sampling was significantly higher (P = 0.02). There was a statistically significant coexistence between BK and JC viruses among our patients (P = 0.029). The frequency of JCV viruria in males was reported almost three times more than in females (P = 0.005). The JCV shedding in urine was significantly associated with the tropical steroids like prednisolone acetate, which have been the standard regimen (P = 0.039). Multivariable analysis revealed duration of post-transplantation (OR, 0.89; P = 0.038), diabetes mellitus (OR, 1.85; P = 0.034), and renal stone (OR 1.10; P = 0.04) as independent risk factors associated with JCV viremia post-renal transplantation.
CONCLUSION
It seems that the discovery of potential risk factors, including immunological and non-immunological elements, may offer a possible preventive or therapeutic approach in the JCV disease episodes. The results of this study may also help clarify the probable clinical risk factors involving in progressive multifocal leukoencephalopathy development.
Identifiants
pubmed: 35941650
doi: 10.1186/s12985-022-01843-w
pii: 10.1186/s12985-022-01843-w
pmc: PMC9358911
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Informations de copyright
© 2022. The Author(s).
Références
Transplantation. 2007 Aug 15;84(3):323-30
pubmed: 17700156
Cancer Control. 2017 Oct-Dec;24(4):1073274817729901
pubmed: 28975841
Transpl Int. 2009 Jul;22(7):688-93
pubmed: 19220823
Transplantation. 2003 Dec 15;76(11):1653-5
pubmed: 14702550
PLoS One. 2011 Jan 31;6(1):e14630
pubmed: 21297941
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):244-8
pubmed: 22549384
J Gen Virol. 2010 Dec;91(Pt 12):3042-52
pubmed: 20826618
J Res Med Sci. 2011 Jul;16(7):916-22
pubmed: 22279460
J Clin Virol. 2017 Nov;96:7-11
pubmed: 28915452
Am J Surg. 2010 Jul;200(1):53-8
pubmed: 20637336
Lancet. 1971 Jun 19;1(7712):1253-7
pubmed: 4104714
Nucleic Acids Res. 1993 Apr 25;21(8):1959-64
pubmed: 8388103
Virus Res. 2020 Mar;278:197860
pubmed: 31911182
Blood Adv. 2017 Oct 18;1(23):2041-2045
pubmed: 29296850
J Virol. 2006 Nov;80(21):10506-13
pubmed: 16928756
J Med Virol. 2008 Dec;80(12):2147-52
pubmed: 19040292
J Int Med Res. 2017 Apr;45(2):762-770
pubmed: 28415933
J Med Virol. 2004 Apr;72(4):675-8
pubmed: 14981772
Clin Microbiol Rev. 2012 Jul;25(3):471-506
pubmed: 22763635
Blood. 2013 Jun 6;121(23):4694-702
pubmed: 23613524
Virol J. 2015 Nov 24;12:196
pubmed: 26596376
J Med Virol. 2011 Jan;83(1):132-6
pubmed: 21108350
Kidney Int Rep. 2019 May 17;4(7):939-945
pubmed: 31317116
Ochsner J. 2010 Winter;10(4):245-9
pubmed: 21603392
Microbiol Immunol. 2010 Dec;54(12):758-62
pubmed: 21223365
J Gen Virol. 2009 Aug;90(Pt 8):2005-2014
pubmed: 19420158
J Clin Virol. 2010 Oct;49(2):137-40
pubmed: 20667770
Microb Pathog. 2016 Aug;97:204-8
pubmed: 27317859
J Neurovirol. 2015 Dec;21(6):632-6
pubmed: 25227934
Clin Dev Immunol. 2013;2013:926391
pubmed: 23424601
Transplantation. 2016 Nov;100(11):2276-2287
pubmed: 27391196
Lancet. 1971 Jun 19;1(7712):1257-60
pubmed: 4104715
Transplant Proc. 2015 Apr;47(3):660-5
pubmed: 25891706
Arch Virol. 2015 Jan;160(1):61-8
pubmed: 25218012
Transpl Infect Dis. 2011 Feb;13(1):89-92
pubmed: 21299772
J Am Soc Nephrol. 2011 May;22(5):825-31
pubmed: 21511831
Diagn Microbiol Infect Dis. 2019 Nov;95(3):114859
pubmed: 31320237
J Neuroimmune Pharmacol. 2019 Dec;14(4):649-660
pubmed: 31452013
Transpl Infect Dis. 2011 Dec;13(6):633-7
pubmed: 21414116
Gastroenterol Hepatol Bed Bench. 2012 Spring;5(2):84-9
pubmed: 24834205
Neurol Clin. 1984 May;2(2):299-313
pubmed: 6503939
J Clin Pathol. 2010 Aug;63(8):714-8
pubmed: 20702473
Neurol India. 2010 Jan-Feb;58(1):118-21
pubmed: 20228479
J Med Virol. 2005 Oct;77(2):238-43
pubmed: 16121361
Transplantation. 2019 Jun;103(6):1224-1233
pubmed: 30130322
Prog Clin Biol Res. 1983;105:107-17
pubmed: 6304747
Transplantation. 2001 May 15;71(9):1300-3
pubmed: 11397966
Clin Infect Dis. 2018 Jul 2;67(2):275-282
pubmed: 29635465
Am J Transplant. 2005 May;5(5):1151-8
pubmed: 15816900
Intervirology. 2013;56(4):249-52
pubmed: 23652381